Department of Cardiology, Medicine Faculty, Dicle University Diyarbakir, Turkey.
Eur Rev Med Pharmacol Sci. 2012 May;16(5):617-21.
Aspirin reduces the odds of an arterial thrombotic event in high-risk patients. However, 10%-20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term followup. Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM). The aim of this study was to assess aspirin resistance and to compare it to the use of oral anti-diabetic drugs and insulin in patients with diabetes.
Platelet aggregation was measured after aspirin treatment in 101 diabetic patients undergoing percutaneous coronary intervention. Two patient populations were included in the investigation: use of insulin (group 1) and use of oral anti-diabetic agents (OAD) (group 2) in diabetic patients. Platelet aggregation was determined using a multichannel Multiplate analyzer. Among group 1 patients, 4.7% were aspirin non-responders and among group 2 patients, 8.6% were aspirin non-responders. Statistical differences were not found between the groups (p = 0.359).
This study demonstrated that there was no significant difference in aspirin resistance between type 2 diabetes mellitus patients on insulin treatment and type 2 diabetes mellitus patients on OAD treatment.
阿司匹林可降低高危患者发生动脉血栓事件的几率。然而，在长期随访中，10%-20%接受阿司匹林治疗的动脉血栓事件患者会再次发生动脉血栓事件。在某些患者群体中，如急性冠脉综合征、缺血性卒中等，已经描述了阿司匹林抵抗的现象。经皮冠状动脉介入治疗（药物洗脱支架）、支架再狭窄和糖尿病（DM）。本研究旨在评估阿司匹林抵抗，并将其与糖尿病患者使用口服降糖药物和胰岛素进行比较。
对 101 例接受经皮冠状动脉介入治疗的糖尿病患者进行了阿司匹林治疗后的血小板聚集检测。该研究纳入了两个患者群体：使用胰岛素（组 1）和使用口服降糖药物（OAD）（组 2）的糖尿病患者。采用多通道 Multiplate 分析仪测定血小板聚集。在组 1 患者中，有 4.7%的患者对阿司匹林无反应，而在组 2 患者中，有 8.6%的患者对阿司匹林无反应。两组之间未发现统计学差异（p = 0.359）。
本研究表明，接受胰岛素治疗的 2 型糖尿病患者和接受 OAD 治疗的 2 型糖尿病患者之间，阿司匹林抵抗无显著差异。
